黄璐琦:用十九大精神推动中医药事业传承发展

2017-12-22 黄璐琦 中国中医

习近平总书记在十九大报告中指出,中国特色社会主义进入新时代,我国社会主要矛盾已经转化为人民日益增长的美好生活需要和不平衡不充分的发展之间的矛盾。这是对我国发展新的历史方位的科学判断,准确反映了中国特色社会主义在长期建设中取得的历史性成就、党和国家事业发生的历史性变革,准确反映了党的十八大以来取得的全方位、开创性成就和深层次、根本性变革。成就的取得是以习近平同志为核心的党中央迎难而上、开拓进取、革故

习近平总书记在十九大报告中指出,中国特色社会主义进入新时代,我国社会主要矛盾已经转化为人民日益增长的美好生活需要和不平衡不充分的发展之间的矛盾。这是对我国发展新的历史方位的科学判断,准确反映了中国特色社会主义在长期建设中取得的历史性成就、党和国家事业发生的历史性变革,准确反映了党的十八大以来取得的全方位、开创性成就和深层次、根本性变革。成就的取得是以习近平同志为核心的党中央迎难而上、开拓进取、革故鼎新、励精图治,团结带领全党全军全国各族人民共同奋斗的结果。

牢记新时代赋予我们的责任和使命

十九大吹响了全党全国人民走进中国特色社会主义新时代,向中华民族伟大复兴中国梦前进的集结号、冲锋号,我们必须不忘初心、牢记使命,深刻领会习近平新时代中国特色社会主义思想的精神实质和丰富内涵,以习近平新时代中国特色社会主义思想引领新征程。按照中央关于认真学习宣传贯彻党的十九大精神决定中的“十个深刻领会”,进一步增强“四个意识”,自觉在思想上政治上行动上维护以习近平同志为核心的党中央权威和集中统一领导。全面准确把握习近平新时代中国特色社会主义思想,不断提升理论联系实际的能力,以学促干、知行合一,奋力在新时代干出新气象、实现新作为。全面准确把握我国社会主要矛盾已经转化等重大政治论断的深远影响和实现“两个一百年”奋斗目标的战略部署,主动承担起新时代的历史使命,为中医药事业创新发展贡献力量。

党的十九大报告提出了“坚持中西医并重,传承发展中医药事业”,充分体现了以习近平同志为核心的党中央对中医药工作的高度重视和新期待新要求。

“中医药学是中国古代科学的瑰宝,也是打开中华文明宝库的钥匙”“切实把中医药这一祖先留给我们的宝贵财富继承好、发展好、利用好”,习近平总书记在祝贺中国中医科学院成立60周年的贺信中对中医药给予了高度评价,同时也对科研工作者提出了发展要求,希望广大中医药工作者增强民族自信,勇攀医学高峰,深入发掘中医药宝库中的精华,充分发挥中医药的独特优势,推进中医药现代化,推动中医药走向世界,切实把中医药这一祖先留给我们的宝贵财富继承好、发展好、利用好,在建设健康中国、实现中国梦的伟大征程中谱写新的篇章。

中医药的发展与创新,需要“到哪里去、如何去”的终极性追问,更需要了解“从哪里来、如何来”的源头问题。所谓“继承好”是要“重访”,不是不经研究地复古,而是重新了解它的“正形”。古史辨运动之后,出现了疑古、信古、释古三派。如果没有经过激烈的疑古,他们不会注意到要先把先秦材料提起来抖一抖,再放下来重估其价值。没有经过这一番震荡,不可能有“释古”“考古”。

借用当代新儒学重要人物牟宗三先生的话“要经过几度的‘自我坎陷’之后,才能重新去掌握历史文化的‘正形’。”不好好理解旧的不足以知新,不足以挖掘出多元、细微、细致而有创造力的资源。

习近平总书记说:“实践没有止境,理论创新也没有止境;我们必须在理论上跟上时代,不断认识规律,不断推进理论创新、实践创新、制度创新、文化创新以及其他各方面创新。”发展好、利用好要求切实做好创新发展,使其为解决人类问题贡献更多的中国智慧和中国方案,但目前有些方面尚显不足,比如,对中医药原创思维弱化不够重视,学术研究多集中在以还原论的观念、方法和技术对传统中医药的有关内容进行验证、诠释,寻找中医药诊疗疾病的物质基础等,缺少与中医药学术特色相对应的传统科研思维研究。

对此,每一位中医药科研工作者站在中华民族强起来的新时代,都应增强使命感和责任感。

建立符合中医药特点的科研新思路

要做到“继承好发展好利用好”,首先应当立足自身,不断提高中医药创新发展能力。打铁还需自身硬,必须认清新形势,把握新常态,适应新要求,勤于学习,勇于实践,善于总结,敢于创新,不断提升自己,切实树立紧迫感和忧患意识,敢于不可为而为之,迎接新挑战,站在更高的起点和层次上乘势而上,顺势而为,力求在解决重大问题、深层次问题上求突破。

其次要建立符合中医药特点的科研思路与方法,发挥中医药原创优势。运用现代科学技术和传统中医药研究方法,充分体现中医药特点和规律,深化中医药基础理论研究,建立概念明确、结构合理的理论框架体系;探索适合中药特点的新药开发模式和中药资源保护与利用模式,推进中药资源和中药产业永续发展。

最后应当推动科技成果的转化和普及。中医药事业要腾飞,必须要有健全的两翼,一翼是科学研究,一翼是科技普及。要大力推广中医药科研成果和适宜技术,推动科技成果转化为生产力,夯实中医药群众基础,把科技成果应用在实现现代化的伟大事业中。

在传承和发展中医药事业的科研工作中,要做到:研究创新不忘求实,综合交叉不失本体,融入世界不丢传统,建设发展不离根基。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978072, encodeId=9eab19e8072ef, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 05 17:48:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675562, encodeId=7d8116e5562b8, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Tue Feb 06 10:48:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636295, encodeId=75d116362954d, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Fri Aug 03 13:48:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409239, encodeId=e7a2140923905, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557968, encodeId=8cc9155e96853, content=<a href='/topic/show?id=9d09214948d' target=_blank style='color:#2F92EE;'>#中医药事业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21494, encryptionId=9d09214948d, topicName=中医药事业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549e14938166, createdName=amy0555, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585277, encodeId=e53415852e7c8, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978072, encodeId=9eab19e8072ef, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 05 17:48:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675562, encodeId=7d8116e5562b8, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Tue Feb 06 10:48:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636295, encodeId=75d116362954d, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Fri Aug 03 13:48:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409239, encodeId=e7a2140923905, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557968, encodeId=8cc9155e96853, content=<a href='/topic/show?id=9d09214948d' target=_blank style='color:#2F92EE;'>#中医药事业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21494, encryptionId=9d09214948d, topicName=中医药事业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549e14938166, createdName=amy0555, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585277, encodeId=e53415852e7c8, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
    2018-02-06 lishizhe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978072, encodeId=9eab19e8072ef, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 05 17:48:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675562, encodeId=7d8116e5562b8, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Tue Feb 06 10:48:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636295, encodeId=75d116362954d, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Fri Aug 03 13:48:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409239, encodeId=e7a2140923905, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557968, encodeId=8cc9155e96853, content=<a href='/topic/show?id=9d09214948d' target=_blank style='color:#2F92EE;'>#中医药事业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21494, encryptionId=9d09214948d, topicName=中医药事业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549e14938166, createdName=amy0555, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585277, encodeId=e53415852e7c8, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978072, encodeId=9eab19e8072ef, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 05 17:48:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675562, encodeId=7d8116e5562b8, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Tue Feb 06 10:48:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636295, encodeId=75d116362954d, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Fri Aug 03 13:48:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409239, encodeId=e7a2140923905, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557968, encodeId=8cc9155e96853, content=<a href='/topic/show?id=9d09214948d' target=_blank style='color:#2F92EE;'>#中医药事业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21494, encryptionId=9d09214948d, topicName=中医药事业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549e14938166, createdName=amy0555, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585277, encodeId=e53415852e7c8, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
    2017-12-24 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=1978072, encodeId=9eab19e8072ef, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 05 17:48:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675562, encodeId=7d8116e5562b8, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Tue Feb 06 10:48:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636295, encodeId=75d116362954d, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Fri Aug 03 13:48:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409239, encodeId=e7a2140923905, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557968, encodeId=8cc9155e96853, content=<a href='/topic/show?id=9d09214948d' target=_blank style='color:#2F92EE;'>#中医药事业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21494, encryptionId=9d09214948d, topicName=中医药事业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549e14938166, createdName=amy0555, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585277, encodeId=e53415852e7c8, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1978072, encodeId=9eab19e8072ef, content=<a href='/topic/show?id=5bca258e611' target=_blank style='color:#2F92EE;'>#传承发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25876, encryptionId=5bca258e611, topicName=传承发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Mon Mar 05 17:48:00 CST 2018, time=2018-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675562, encodeId=7d8116e5562b8, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Tue Feb 06 10:48:00 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636295, encodeId=75d116362954d, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Fri Aug 03 13:48:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409239, encodeId=e7a2140923905, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557968, encodeId=8cc9155e96853, content=<a href='/topic/show?id=9d09214948d' target=_blank style='color:#2F92EE;'>#中医药事业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21494, encryptionId=9d09214948d, topicName=中医药事业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=549e14938166, createdName=amy0555, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585277, encodeId=e53415852e7c8, content=<a href='/topic/show?id=c92f1031e3c4' target=_blank style='color:#2F92EE;'>#黄璐琦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103173, encryptionId=c92f1031e3c4, topicName=黄璐琦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd8f17147802, createdName=bluefate127, createdTime=Sun Dec 24 01:48:00 CST 2017, time=2017-12-24, status=1, ipAttribution=)]

相关资讯

中国卫生信息与健康医疗大数据学会中医药专业委员会成立

12月20日,中国卫生信息与健康医疗大数据学会中医药专业委员会成立大会在京召开。国家卫生计生委副主任、中国卫生信息与健康医疗大数据学会会长金小桃,国家中医药管理局副局长闫树江出席会议并致辞。

王国强:推进中医药与互联网深度融合

12月14日,国家卫生计生委副主任、国家中医药管理局局长王国强前往浙江省嘉兴市,深入乌镇互联网国医馆和嘉兴市、桐乡市中医医院调研,强调要认真研究实施中医药大数据战略,加快推进中医药健康服务与互联网融合发展,更好地传承发展中医药事业,更好地满足人民群众对中医药服务的需求。

邱德亮:把落实十九大精神转化为中医药行业发力点

党的十九大,我认真收看了全程,包括每一个场面和细节,都让人感觉振奋和激动。我认识到,十九大发出的号召是党的呼唤,是人民的心声,中医药系统面临事业发展的新时代,一定要不负这个时代,要系统学习领会十九大精神实质,把落实十九大精神转化为中医药行业的发力点。

中伊签署传统医学合作谅解备忘录,促进中医药和波斯医药在两国的发展

12月19日,在国家卫生和计划生育委员会主任李斌、伊朗卫生和医学教育部部长赛义德·哈桑·戈兹扎德·哈什米(Seyed Hassan Ghazizadeh Hashemi)共同见证下,国家中医药管理局副局长王志勇与伊朗卫生部部长资深顾问达伍德·丹尼斯·贾法里(Davood Danesh Jafari)在京签署《中华人民共和国国家中医药管理局与伊朗伊斯兰共和国卫生和医学教育部传统医学合作谅解备忘录》。

频繁奔波开药太折腾?看中医药如何打通慢病服务最后一公里

福建省厦门市坚持“三师共管”分级诊疗和中医适宜技术相结合,开展市中医院专家基层师带徒,提升社区医生中医药服务能力,完善了慢病分级诊疗工作。

全国首批102名中医药传承博士后出站

经过4年临床跟师,我国首批102名中医药传承博士后正式出站。“传承博士后制度就是要解决高层次人才这头薄的问题。”12月16日,中国工程院院士、中国中医科学院院长张伯礼在全国中医药学术思想传承与博士后研究高峰论坛上表示。